4R-	Four-repeat
AChE	Acetylcholinesterase inhibitors
AD	Alzheimer’s disease
AGD	Argryophilic grain disease
ALS	Amyotrophic sclerosis
APP	Amyloid precursor protein
ASO	Antisense oligonucleotide therapy
ASO	Antisense oligonucleotide therapy
ATP	Adenosine 5′-triphosphate
Aβ	Amyloid beta
BBB	Blood–brain barrier
CBD	Corticobasal degeneration
CNS	Central nervous system
DMT	Disease-modifying therapy
DNA	Deoxyribonucleic acid
EOAD	Early-onset Alzheimer’s disease
FDA	Food and Drug Administration
FTD	Frontotemporal dementia
FTDP	Frontotemporal dementia and parkinsonism
GABBA	Gamma-aminobutyric acid
GRN	Gene and progranulin
GWAS	Genome-wide association studies
IFN	Interferon
LOAD	Late-onset Alzheimer’s disease
LTP	Long-term potentiation
MAPT	microtubule-associated protein tau
MCI	mild cognitive impairment
mRNA	messenger ribonucleic acid
NFT	Neurofibrillary tangles
NFT	neurofibrillary tangles
NMDA	N-methyl-D-aspartate
OGA	O-GlcNAcase
OGT	O-GlcNAc transferase
PD	Parkinson’s disease
PDPK	proline-directed protein kinases
PHF	Paired helical filament
PTM	Post translational modification
RNA	ribonucleic acid
ROS	reactive oxidative species
TGF	transforming growth factor
TNF	tumor necrosis factor
U.S.	United States